Telix Pharmaceuti…
USUSDTelix Pharmaceuticals Limited (US:TLPPF) — Biotechnology: Pharmaceutical Preparations. Número de bolsas en las que cotizan las acciones de la empresa: 1. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la empresa
- Sitio web
- telixpharma.com
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sede central
- NORTH MELBOURNE, Australia
- Consejero delegado
- Mr. Raphael Ortiz L.L.B., M.B.A.
- Empleados
- 1 120
- Acciones en circulación
- 338.78 M a 2025-12-31
- Capital flotante
- 273.61 M
- Capitalización bursátil
- 3.82 mil M USD
- Insiders
- 15.83%
- Inversores institucionales
- 34.22%
- Industria (SIC)
- Pharmaceutical Preparations
Descripción
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Bolsas y tickers
| Bolsa | Ticker | Moneda | Precio | Tipo |
|---|---|---|---|---|
| US USA Stocks | TLPPF | USD | 10.95 +1.39% | acciones ordinarias |
Dividendos
No se han encontrado pagos de dividendos (comprobado el 07.10.2026). Es probable que la empresa no reparta dividendos.
Noticias de esta semana
Aún no hay noticias del sitio web de la empresa.
Principales accionistas
| Titular | Participación | Acciones | Fecha del informe |
|---|---|---|---|
| Behrenbruch (Christian P… | ≈6.31% | 21.4 M | 2026-04-29 |
| VANGUARD STAR FUNDS-Vang… | 1.21% | 4.1 M | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.81% | 2.74 M | 2026-06-30 |
| DFA INVESTMENT TRUST CO-… | 0.33% | 1.13 M | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.19% | 652 331 | 2026-07-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.18% | 613 527 | 2026-05-31 |
| Fidelity Rutland Square… | 0.1% | 339 965 | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.09% | 298 322 | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.07% | 233 321 | 2026-07-31 |
| College Retirement Equit… | 0.06% | 202 548 | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.05% | 156 851 | 2026-07-31 |
| Olson (Tiffany) (Indepen… | ≈0.03% | 106 550 | 2025-03-05 |
| McDonald (Marie Elizabet… | ≈0% | 3 719 | 2025-03-05 |
| Kluge (Andreas) (Former) | — | 0 | 2024-10-17 |
| McCann (Harry Kevin) (Fo… | — | 0 | 2025-05-21 |
